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Abstract
Background/objectives Low vitamin B12 and folate levels in community-dwelling older people are usually corrected with
supplements. However, the effect of this supplementation on haematological parameters in older persons is not known.
Therefore, we executed a systematic review and individual participant data meta-analysis of randomised placebo-controlled
trials (RCTs).
Subjects/methods We performed a systematic search in PubMed, EMBASE, Web of Science, Cochrane and CENTRAL for
RCTs published between January 1950 and April 2016, where community-dwelling elderly (60+ years) who were treated
with vitamin B12 or folic acid or placebo. The presence of anaemia was not required. We analysed the data on haemato-
logical parameters with a two-stage IPD meta-analysis.
Results We found 494 full papers covering 14 studies. Data were shared by the authors of four RCTs comparing vitamin
B12 with placebo (n= 343) and of three RCTs comparing folic acid with placebo (n= 929). We found no effect of vitamin
B12 supplementation on haemoglobin (change 0.00 g/dL, 95% CI: −0.19;0.18), and no effect of folic acid supplementation
(change −0.09 g/dL, 95% CI: −0.19;0.01). The effects of supplementation on other haematological parameters were similar.
The effects did not differ by sex or by age group. Also, no effect was found in a subgroup of patients with anaemia and a
subgroup of patients who were treated >4 weeks.
Conclusions Evidence on the effects of supplementation of low concentrations of vitamin B12 and folate on haematological
parameters in community-dwelling older people is inconclusive. Further research is needed before ﬁrm recommendations
can be made concerning the supplementation of vitamin B12 and folate.
Background
The prevalence of anaemia in older persons is high (around
10% among people aged ≥65 years) and rises with advan-
cing age [1, 2]. In about one-third of older persons with
anaemia co-incidental nutritional deﬁciencies, such as iron,
vitamin B12 and folate deﬁciency, exist [2]. Among people
aged ≥75 years, the prevalence of both vitamin B12 and
folate deﬁciency is >10% [3–7]. These deﬁciencies are not
only associated with macrocytic anaemia but also with
dementia, peripheral neuropathy, combined degeneration of
the spinal cord and cardiovascular disease [8–11].
As the prevalence of deﬁciencies in vitamin B12 and
folate are high, screening for deﬁciencies in vitamin B12
and folate has been recommended as part of a geriatric
work-up [12, 13]. Guidelines recommend vitamin
B12 supplementation in patients with very low serum
vitamin B12 concentrations due to lack of intrinsic factor
(IF) (pernicious anaemia) or food-vitamin B12 malabsorp-
tion. Several studies have shown signiﬁcant increases in
haemoglobin after vitamin B12 administration in these
patients [14–16]. Thus, when low levels of vitamin B12 and
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folate are found, patients are often treated with injections or
oral supplements [9, 11, 17].
Interestingly, evidence of an association between a low
serum vitamin B12 concentration and anaemia in older
individuals in the general population is limited and incon-
clusive. Data from the Leiden 85-plus study showed that
low vitamin B12 concentrations (<150 pmol/L) in 85-year-
old persons are not associated with anaemia [18]. Also, the
effect of vitamin B12 supplementation on haemoglobin and
mean corpuscular volume (MCV) in elderly with low levels
of vitamin B12 is unclear [19].
In contrast to vitamin B12 deﬁciency, folate deﬁciency
seems to be associated with the presence and the develop-
ment of anaemia in older individuals [18]. Therefore, early
detection of folate deﬁciency may identify older individuals
at risk of anaemia. Preventive folic acid supplementation or
folic acid fortiﬁcation of grain and cereal products has been
recommended and has already been initiated at population
level in several countries. However, to date, it is not known
if older persons beneﬁt from prophylactic folic acid sup-
plementation with regards to haemoglobin levels, as no
evidence is available to support this assumption.
In order to evaluate the effect of vitamin B12 and folic
acid supplementation on haematological parameters in
elderly, we executed a systematic review and individual
participant data meta-analysis of randomised placebo-
controlled trials.
Methods
Criteria for considering studies for this meta-
analysis
We considered all randomised controlled trials (RCTs),
where community-dwelling elderly (60+ years) were trea-
ted with vitamin B12 or folic acid (all dosages and all forms
of administration) and were compared with elderly who
were given a placebo. The presence of anaemia or a vitamin
B12/folate deﬁciency was not required for inclusion.
Exclusion criteria were: mean or median age less than 60
years, no availability of haemoglobin concentrations or
haematocrit at baseline and during follow-up, combinations
of vitamin B12 and folic acid supplementation, and speciﬁc
populations (e.g., studies in diabetes patients or patients
with renal failure).
Search strategy
We performed a search on PubMed, EMBASE, Web of
Science, Cochrane and CENTRAL with relevant MeSH-
headings and title words for vitamin B12 and folic acid for
randomised controlled trials (RCTs) published between
January 1950 and April 2016. Case reports and letters were
excluded. We also searched ClinicalTrials.gov for (ongo-
ing) trials on vitamin B12 or folic acid supplementation in
older persons. We also used backward and forward citation
screening. The electronic search was performed by an
information scientist from the Walaeus Library of the Lei-
den University Medical Center. The exact search strategy
can be found in Supplementary File 1.
Selection of studies
All titles and abstracts found in the electronic databases
were assessed by the last author. Full copies were acquired
of articles that were potentially relevant or in case of
uncertainty. WPJdE and LWB appraised these full copies.
Disagreement was resolved by consensus. Investigators
from each eligible study were invited to join the project and
to share their data. The risk of bias of the included studies
was assessed using the Cochrane risk of bias assessment
table (see Supplemental File 3).
Data collection
We centrally collected data on demographic characteristics,
pre- and post-treatment concentrations of serum vitamin
B12, serum/red cell folate, homocysteine, methylmalonic
acid, haemoglobin, as well as on levels of haematocrit,
mean corpuscular volume (MCV) and red blood cell count
(RBC) for all individuals included in the studies. Since
vitamin B12 and folate deﬁciency is deﬁned ideally in terms
of serum values of vitamin B12 and folate in combination
with homocysteine and methylmalonic acid [8], we also
collected data on homocysteine and methylmalonic acid,
when available.
Analyses
We combined the results of the individual studies into two
meta-analyses; one on the effect of vitamin
B12 supplementation and one on the effect of folic acid
supplementation on haematological parameters. We per-
formed a two-stage individual participant data meta-
analysis. First, for all individual studies separately, we
calculated the mean change in haematological parameters
between baseline and follow-up (i.e., follow-up minus
baseline) in the active treatment group, and in the placebo
group (IBM SPSS Statistics 20). Subsequently, we calcu-
lated the difference in mean change (together with its
standard error) between the active treatment group and
placebo group. Then, pooled estimates for each outcome
were calculated using a ﬁxed-effects model, using Review
Manager version 5.3.3. The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014. We measured statistical
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heterogeneity using the I2 statistic. An I2 value greater than
50% indicates at least moderate statistical heterogeneity
[20].
We performed subgroup analyses for sex and age.
Interaction between treatment and sex, and treatment and
age, was evaluated by linear regression analysis. Further
post hoc analyses were performed in the subgroup of par-
ticipants with anaemia at baseline, in MCV subgroups, and
in studies with a short (≤4 weeks) vs. long duration of
treatment (>4 weeks).
Results
Selection of studies
The electronic search identiﬁed 5691 potentially relevant
titles and abstracts of papers (performed 25-3-2016). We
identiﬁed 494 papers, of which 47 fulﬁlled our inclusion
criteria (Fig. 1). Investigators from these studies were
invited to join the project and to share their data. Eight
authors could not provide haematological data because
these were not measured or because individual data were
not available anymore. Seven authors did not respond to our
request [21–27]. The authors of the other 32 papers (n= 10
for vitamin B12 and n= 22 for folic acid) agreed to parti-
cipate in this project and to share their data on haemoglobin
concentrations or haematocrit fractions after supplementa-
tion. These 32 papers comprised 4 unique studies on vita-
min B12 supplementation [28–31] and 3 unique studies on
folic acid supplementation (Table 1) [32–34]. No additional
(ongoing) studies were found on ClinicalTrials.gov. The
risk of bias of included studies was low (see Supplemental
File 3).
Table 1 describes a summary of the characteristics of the
included studies. The sample sizes of the included studies
varied from ‘n= 24’ [33] to ‘n= 802’ [32]. Also, the
dosage and the forms of administration and the time to
follow-up varied to a great extent (Table 1).
Heterogeneity
We found no indications for statistical heterogeneity in the
studies on vitamin B12 (I2= 0%) for all four outcomes, but
for the studies on folic acid we found indications for at least
moderate statistical heterogeneity (I2= 72%) when analys-
ing RBC as an outcome. Also, clinical heterogeneity existed
between studies due to different methods of administration,
Fig. 1 Schematic representation
of the selection of publications
for this meta-analysis
An IPD meta-analysis on the effect of vitamin B12 and folic acid supplementation in older people
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dosage of vitamin B12 and folic acid, outcomes and follow-
up time. Therefore, we show both the results of the indi-
vidual studies and the results of the pooled effect estimates
(Table 2).
Results of analyses
In Table 2, we show the baseline values of haemoglobin,
vitamin B12 and folate. The number of individuals with
anaemia was relatively small. None of the individual studies
showed a signiﬁcant effect of vitamin B12 (total n= 343) or
folic acid supplementation (total n= 929) on changes in
haematological parameters, except for the study by Ntaios
on RBC (Table 3). The pooled estimate of the effect on
haemoglobin was 0.00 g/dL (95% CI: −0.19;0.18) for
vitamin B12 supplementation and −0.09 g/dL (95% CI:
−0.19;0.01) for folic acid supplementation, meaning that
there was no difference in the mean change in haemoglobin
concentrations during follow-up between vitamin B12 and
placebo, and folic acid and placebo.
In addition, no differences in the mean change in other
haematological parameters were observed. For vitamin
B12 supplementation, the pooled estimate of the effect was
0.00 g/dL (95% CI: −0;0.01) for haematocrit, 0.07 g/dL
(95% CI: −0.58;0.72) for MCV and 0.00 g/dL (95% CI:
−0.06;0.06) for RBC. For folic acid supplementation, the
pooled estimate of effect was 0.00 g/dL (95% CI: −0.01;0)
for haematocrit, −0.37 g/dL (95% CI: −0.82;0.08) for
MCV and −0.02 g/dL (95% CI: −0.05;0.02) for RBC.
Subgroup analyses
In none of the subgroups on sex and age, a signiﬁcant effect
of vitamin B12 or folic acid supplementation on hae-
moglobin concentrations was found (Table 4). The effect of
vitamin B12 and folic acid on haemoglobin was the same
for men and women (Pinteraction= 0.577 for vitamin B12 and
Pinteraction= 0.545 for folic acid) or between different age
groups (Pinteraction= 0.793 for vitamin B12 and Pinteraction=
0.836 for folic acid). Similar results were found when we
repeated the analyses for haematocrit, MCV and RBC (data
not shown).
Post hoc analyses
When we repeated the analyses in participants with anae-
mia, we did not observe differences in the change in hae-
moglobin levels between those who were treated with
vitamin B12 and those treated with placebo (Table 4). In
those treated with folic acid, a signiﬁcantly larger decline in
haemoglobin levels was observed (Table 4). Moreover,
when we stratiﬁed on MCV (<80, 80–100 and >100 fL), in
none of the subgroups we observed an effect of vitamin B12
or folic acid administration on haemoglobin. In addition, no
effect on haemoglobin was found in studies with treatment
duration of ≤4 weeks or in studies with a treatment duration
of >4 weeks, both with vitamin B12 and folic acid (Table
4).
Results from studies without individual participant
data
Of the seven studies that could not be included because of a
lack of response from the authors, four studies did not report
having measured haemoglobin and/or haematocrit levels.
We here discuss the three studies that reported having
measured haemoglobin and/or haematocrit levels but of
which we did not retrieve data (see Supplemental File 2).
The ﬁrst study, by Smidt et al., measured haemoglobin
and haematocrit at baseline [25], but did not report hae-
matological data at follow-up. The second study, by Hughes
et al., measured haemoglobin at baseline and at follow-up
[26]. In their study, 93 men and 132 women were given
intramuscular hydroxocobalamin (1000 µg.), twice in the
ﬁrst week and then at weekly intervals for a further 4 weeks.
During their study, there was a small fall in haemoglobin
level, but the difference between the mean changes in those
given B12 and those given placebo was small and not sta-
tistically signiﬁcant (0.01 ± 0.35 g.). In the third study by
Rampersaud et al. in 33 healthy, postmenopausal women
aged 60–85 years, treatment groups received two different
folate repletion intakes (i.e., ≈200 and ≈400 µg folate/d)
[23]. In this study, haematocrit values did not change sig-
niﬁcantly over the 14-week study period.
Discussion
In this individual participant data meta-analysis, we did not
observe any signiﬁcant measurable change in routine hae-
matological parameters after treatment with vitamin B12 or
folic acid in older persons with either normal or vitamin
B12 or folate concentrations below the reference range.
There are several possible explanations for the lack of
effect. First, some studies consisted mostly of participants
without vitamin B12 or folate deﬁciency or just below the
cutoff values. As these participants may not have had a true
tissue deﬁciency of vitamin B12 or folate, this may have
diluted the effect of supplementation. Second, many of the
included studies mainly consisted of participants without
anaemia. Perhaps haemoglobin levels in non-anaemic
patients are less likely to increase in response to vitamin
B12 or folic acid treatment than haemoglobin levels in
anaemic patients [29]. Unfortunately, the low numbers of
people with anaemia refrained us from drawing deﬁnite
conclusions on the effects of supplementation in an anaemic
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population with low vitamin B12 or folate concentrations.
Third, a low vitamin B12 or folate concentration alone may
not be the only reason to develop anaemia, and treatment of
these low levels may not be sufﬁcient to raise haemoglobin
levels. Other genetic or environmental factors may be
involved in the onset of anaemia [19]. Also, other causes
such as chronic inﬂammation may play a role in the
development of anaemia [35].
Macrocytic anaemia is one of the most well-known
consequences of vitamin B12 and folate deﬁciency. An
elevated mean corpuscular volume (MCV) is often seen as
an indication to test for the presence of vitamin B12 or
Table 2 Baseline values of haematological parameters and vitamin B12/folate (mean [SD])
Author Intervention group Control group
Studies on B12
Dangour [28] Haemoglobin (g/dL) 14.0 (1.1) 13.8 (1.2)
Haematocrit (fraction) 41 (3) 41 (3)
Anaemic individuals (n) 3 of 80 10 of 75
Vitamin B12 (pmol/L) 232 [52] 237 [60]
B12 deﬁciency (n) 3 of 80 4 of 75
Favrat [29] Haematocrit (fraction) 40.4 (3.9) 39.8 (4.6)
Anaemic individuals (n) 10 of 23 7 of 22
Vitamin B12 (pmol/L) 167 (23) 155 (20)
B12 deﬁciency (n) 8 of 23 12 of 22
Hvas [30] Haemoglobin (g/dL) 13.1 (1.4) 13.5 (1.2)
Anaemic individuals (n) 16 of 67 12 of 70
Vitamin B12 (pmol/L) 303 (159) 277 [92]
B12 deﬁciency (n) 1 of 67 1 of 70
Seal [31, 1] Haemoglobin (g/dL) 12.4 (1.4) 13.2 (1.3)
Anaemic individuals (n) 6 of 12 4 of 14
Vitamin B12 (pmol/L) 135 (27) 143 (21)
B12 deﬁciency (n) 9 of 12 7 of 14
Seal [31, 2] Haemoglobin (g/dL) 13.2 (1.7) 13.2 (1.3)
Anaemic individuals (n) 4 of 14 4 of 14
Vitamin B12 (pmol/L) 153 [39] 143 (21)
B12 deﬁciency (n) 10 of 14 7 of 14
Studies on folic acid
Durga [32] Haemoglobin (g/dL) 14.2 (1.1) 14.3 (1.1)
Haematocrit (fraction) 44 (4) 44 (4)
Anaemic individuals (n) 22 of 395 21 of 407
Folate (nmol/l) 12.4 (4.3) 12.6 (4.6)
Folate deﬁciency (n) 24 of 395 30 of 407
Pathansali [33] Haemoglobin (g/dL) 13.2 (0.9) 13.0 (0.9)
Haematocrit (fraction) 40 (2) 40 (2)
Anaemic individuals (n) 3 of 12 2 of 12
Folate (nmol/l) 13.8 (5.0) 15.0 (6.0)
Folate deﬁciency (n) 9 of 12 7 of 12
Ntaios [34] Haemoglobin (g/dL) 13.9 (0.7) 14.2 (1.2)
Haematocrit (fraction) 42 (2) 43 (4)
Anaemic individuals (n) 4 of 53 2 of 50
Folate (nmol/l) 19.9 (8.7) 18.2 (6.1)
Folate deﬁciency (n) 0 of 53 0 of 50
Anaemia deﬁned as haemoglobin <12 g/dL (haematocrit <0.4%) for male and <13 g/dL (haematocrit <0.35%) for female individuals
Vitamin B12 deﬁciency deﬁned as B12 <150 pmol/l
Folate deﬁciency deﬁned as folate <7 nmol/l
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folate deﬁciency. However, both the sensitivity and the
speciﬁcity of a high MCV for these deﬁciencies are low [10,
36]. In our study, we did not observe an effect of vitamin
B12 and folic administration on the change in MCV. Also,
we did not observe an effect of vitamin B12 or folic acid on
haemoglobin in the MCV subcategories. We have to be
cautious in interpreting these results as the groups are small
and the heterogeneity between studies is large. However,
these results are in line with previous analyses in the Leiden
85-plus study, where no relationship was found between
vitamin B12 or folate deﬁciency and changes in MCV over
time [18].
This review has some weaknesses. First, there was sub-
stantial clinical heterogeneity between studies, due to dif-
ferences in methods of administration, dose of vitamin B12
and folic acid, outcome measures, treatment follow-up time
and sample size, so the results of the meta-analysis have to
be interpreted with caution. However, the fact that the
results of the individual studies point in the same direction
is reassuring. Second, in the post hoc analyses in the sub-
group with anaemia, we observed a signiﬁcantly larger
decline in haemoglobin levels in those treated with folic
acid. This unexpected ﬁnding may perhaps be explained by
random error due to multiple testing and the low number of
participants this subgroup. Third, we cannot exclude the
possibility of bias as not all studies that were identiﬁed in
our systematic search of the literature could be included,
because some authors did not respond to our request or
individual participant data were no longer available. How-
ever, these studies conﬁrm our ﬁndings as they also did not
observe signiﬁcant changes in haemoglobin or haematocrit
levels [23, 25, 26].
Conclusions
We did not observe any signiﬁcant change in routine hae-
matological parameters after treatment with vitamin B12 or
folic acid in older persons with either normal vitamin B12
or folate concentrations, or concentrations of vitamin B12
or folate below the reference range. However, we cannot
draw ﬁrm conclusions because the amount of studies was
low, relatively few individuals with anaemia could be
included, and the clinical heterogeneity between studies was
substantial. Furthermore, we cannot draw conclusions on
other beneﬁts of supplementation of vitamin B12 or folate
other than haematological outcomes.
Further, well-designed large studies are required to
determine whether vitamin B12 and folic acid supple-
mentation are beneﬁcial for older patients with low vitamin
B12 or folate concentrations and anaemia or prophylactic
effects of these supplements.
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